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Background: 
Primary hyperhidrosis is a disorder of excessive sweating, which shares several features with anxiety disorders 
and has a negative impact on a patient’s quality of life. Oral glycopyrrolate is one of the treatments available. 
There are a few published studies on the use of glycopyrrolate given orally in the treatment of hyperhidrosis. 
Methods: 
Thies is study was a review of case notes in a series of 36 patients with primary hyperhidrosis. We made 
a comparison between the Keller’s scale score of a pre-glycopyrrolate medication group and the Keller’s scale 
score f a post-glycopyrrolate medication group. The Milanez de Campos score, Short Form_36 (SF-36) score, 
Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, and autonomic nervous system 
(ANS) scale score were also compared between the two groups.
Results: 
In the post-glycopyrrolate medication group, there were declines in Keller’s scale, and Milanez de Campos 
scale score and BAI score (P ＜ 0.001). In addition, there were increases in SF_36 score in the post-glycopyrrolate 
medication group (P  = 0.03) However, no changes were seen in, BDI score and ANS score in the 
post-glycopyrrolate medication group (P  ＜ 0.001).
Conclusions: 
Glycopyrrolate is an effective initial method of treating primary hyperhidrosis that, reduces anxiety and 
improve patients’ quality of life. (Korean  J  Pain  2012;  25:  28-32)
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INTRODUCTION 
Hyperhidrosis is a condition of abnormal sweating, in 
which a larger amount of perspiration occurs than is need-
ed to control body temperature. Hyperhidrosis is classified 
i n t o  l o c a l  o r  g e n e r a l  h y p e r h i d r o s i s  a c c o r d i n g  t o  s w e a t  
secretion. 
Hyperhidrosis is also differentiated according to time 
of onset and cause. Primary hyperhidrosis usually occurs 
during  puberty  or  earlier  and  characteristically  has  a 
strong genetic tendency. Secondary hyperhidrosis occurs 
at a much later period and accompanies another disease. 
It is reported that primary hyperhidrosis shows a very good 
response to treatment, and various treatment methods are 
employed [1-4].
The preferred treatment method for primary hyper-
hidrosis should be one that is noninvasive and simple, with 
few complications and a low financial burden. In this re-
gard, oral administration of medication can be a good ini-
tial treatment method.
This  study  investigated  the  effect  of  glycopyrrolate 
administration on symptoms of primary hyperhidrosis and 
other clinical symptoms.
MATERIALS  AND  METHODS
1. Subjects 
Subjects were chosen from patien ts w ho visited our 
pain clinic from January 1, 2007 to December 31, 2009 and 
were diagnosed with primary hyperhidrosis. Treatment for 
hyperhidrosis was explained to the patients, and those who 
decided to take glycopyrrolate were enrolled in the study. 
Selection criteria for subjects were as follows: a) age 
10 or above and less than 80, b) diagnosed with hyper-
hidrosis for the first time in their visit to our clinic, c) pri-
mary hyperhidrosis patients with no underlying diseases as 
confirmed  by  interview,  thyroid  function  test,  electro-
cardiogram, chest X-ray, and blood tests, d) patients with 
no experience of invasive treatment in their medical his-
tory, e) oral administration of medication confirmed to be 
possible by exclusion of asthma, dysuria, ophthalmologic 
disease, and cardiac disease through interview, and f) pa-
tients who were able to fill out questionnaires personally 
or with help from the investigator. 
Prior to beginning the treatment, the effects of the 
medication,  side  effects,  and  warnings  were  sufficiently 
e x p l a i n e d ,  a n d  t r e a t m e n t  p r o c e e d e d  w h e n  c o n s e n t  w a s  
obtained.
2. Method 
Glycopyrrolate 1 mg was administered twice a day as 
the  initial  dosage.  Then,  according  to  the  alleviation  of 
symptoms, the dosage was increased by 2 mg per day up 
t o  a  m a x i m u m  o f  8  m g  p e r  d a y .  I f  c o m p l i c a t i o n s  t h a t 
caused difficulties in everyday life arose after increasing 
the dosage, the dosage was decreased to that directly pre-
ceding the current level. The effect and side effects of the 
medication were examined through weekly questionnaires 
filled out by the subjects, interviews with the investigator, 
and physical examinations. The questionnaire included ba-
sic information such as age, sex, initial occurrence of hy-
perhidrosis,  physical  state,  medical  history,  allergies  to 
medications, underlying disease, family history, and area 
of perspiration. To examine the improvement of hyper-
hidrosis symptoms, subjects were given questionnaires in-
cluding questions from the Keller scale and the Milanez de 
Campos scale, and the scores were compared. The func-
tion of the autonomic nervous system (ANS) was scored 
through a test comprising 90 questions. In addition to ex-
amining  the  direct  symptoms  of  hyperhidrosis,  a  Beck 
Depression Inventory (BDI) [5] and Beck Anxiety Inventory 
(BAI)  [6]  were  conducted  to  examine  the  effect  of  the 
treatment  on  patients’ p s y c h o l o g y .  A  S h o r t  F o r m  3 6  
(SF-36) survey was conducted and analyzed before and 
after administration of medication to examine the changes 
in quality of life, which reflects the physical and psycho-
logical state of the patient [7]. 
3. Statistical analysis
Descriptive statistics were used to obtain the average 
score of each indicator and analyze the characteristics of 
the patients, and a paired T-test was used to analyze the 
changes in the various indicators before and after admin-
istration of medication. Since the variables include some 
that do not follow the normal distribution, a non-para-
metric analysis was carried out using a Wilcoxon sign-
ed-rank test to analyze the changes in the indicators be-
fore and after medication. All analysis used SPSS 12.0.1 
(SPSS Inc., Chicago, IL, USA) for Windows. Statistical sig-
nificance was defined as P ＜ 0.05.30 Korean J Pain Vol. 25, No. 1, 2012
Table 1. Demographic Date and Patient Characteristics in Study
Population
Classification
Sex, male, % (n)
Age, year 
Onset age, year 
Family history, % (n)
Night sweating, % (n) 
41.6% (15)
27.6 ± 14.9
15.2 ± 10.9
25.0% (9)
19.4% (7)
Table 2. Analysis of Side Effect of Glycopyrrolate
Classification % (n)
Dry mouth
Palpitation
Headache
Dizziness
Constipation
Dysuria
Others
27.8% (10)
11.1% (4)
2.8% (1)
 0% (0)
 0% (0)
 0% (0)
8.3% (3)
Fig. 1. Comparison of the Keller scale and the Milanez de 
Campo scale of Pre- and post-glycopyrrolate medication 
groups.
Fig. 2. Comparison of the beck depression inventory (BDI),
beck anxiety inventory (BAI) & autonomic nervous system 
(ANS) scale of pre- and post-glycopyrrolate medication 
groups. 
RESULTS
66 hyperhidrosis patients filled out the questionnaires 
before and after medication. Out of these, 18 were ex-
cluded because they omitted one or more questions while 
completing  the  before  and  after  questionnaires,  and  12 
w e r e  e x c l u d e d  b e c a u s e  o u t p a t i e n t  f o l l o w - u p  w a s  n o t  
possible. Thus, a total of 36 patients were administered 
glycopyrrolate and answered all the questions on the ques-
tionnaire (Table 1). 
The  areas  where  hyperhidrosis  occurred  most  fre-
quently were, in descending order, the hands, feet, axillae, 
head and neck, perineum, and other. 19.4% of the patients 
were confirmed to have symptoms in only one area, while 
27.8% had symptoms in two areas and 52.8% had symp-
toms in three or more areas simultaneously.
When comparing the Keller scale before and after ad-
ministration of glycopyrrolate, 75.0% of patients showed 
an actual decrease in perspiration, and a significant im-
provement was seen, with a mean score before medication 
of 60, compared to a mean score after medication of 35.9. 
It was confirmed that there was an actual decrease in per-
spiration (P ＜ 0001). The Milanez de Campos scale also 
showed significant change; the mean score of 57.9 before 
medication improved to 38.7 after medication, providing 
confirmation that the discomfort level in everyday life had 
also decreased (P ＜ 0.001) (Fig. 1). 
BDI and ANS scores did not show large differences be-
fore and after medication, but the BAI, which indicates an 
anxiety  disorder,  showed  a  significant  decrease  when 
scores before and after administration of medication were 
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While taking medication, 36.1% of patients experienced 
side effects, but none stopped taking the medication due 
to this cause (0%). Side effects identified were oral dryness 
27.8%, palpitations 11.1%, headache 2.8%, and other 8.3% 
(Table 2).
DISCUSSION
Primary  hyperhidrosis  has  an  occurrence  rate  of 
0.6-1.0%  of  the  entire  global  population,  but  among 
Asians, the rate is as high as 10%, including light symp-
toms [2]. For a diagnosis of primary hyperhidrosis, it must 
b e c o n f ir m ed  t h a t  t h e r e is  n o  o t h e r d is ea s e t h a t  c o u l d 
cause the symptoms, which usually appear in areas such 
as  the  hands,  feet,  axillae,  trunk,  and  head  and  neck. 
Perspiration is generally induced or intensified by increases 
in body temperature, exercise, and psychological stimuli. 
The specific mechanism is not yet known, but symptoms 
are thought to be due to a hypersensitive reaction of the 
sympathetic nervous system, and heredity is also thought 
to play a role [4,8]. 
Hyperhidrosis  hinders  the  everyday  life  of  many 
patients.  Increase  of  perspiration  due  to  psychological 
stimuli is a common phenomenon in the general public, but 
when the amount of perspiration is excessive, it can hinder 
the social life of patients, lower their quality of life, and 
may even result in psychological problems such as depres-
sion [4,9]. Therefore, treatment is essential for these pa-
tients, and various treatment methods are being attempted.
Typical methods of treatment include topical applica-
tion of aluminum chloride, ionospheresis, oral medication, 
hypodermic injection of botulinum toxin, sympathetic nerve 
block using alcohol, and sympathectomy. These methods 
each  have  advantages  and  disadvantages  according  to 
their mechanisms of action. Sympathectomy has an ex-
cellent  perspiration  suppression  effect  but  has  serious 
complications of compensatory sweating, and it has a high 
failure rate in facial hyperhidrosis [1,10-12]. Hyperhidrosis 
treatment using botulinum toxin has been frequently used 
recently, but it has limitations, including that it is effective 
only in specific areas such as the axillae, and that it is 
rather expensive [3,13]. On the other hand, the rather in-
expensive method of topical application of aluminum chlor-
ide is also only effective in the axilla area, and it can cause 
allergic responses in the skin. Ionospheresis is also only 
effective in specific areas (axillae, hands, feet), the effect 
i s  r e l a t i v e l y  s m a l l ,  a n d  m a n y  p a t i e n t s  c o m p l a i n  o f  s k i n 
rashes and eruption or burning sensation. 
Oral  medications  used  in  treating  hyperhidrosis  are 
sedative or anticholinergic drugs. Oral medication affects 
the whole body, so there is no compensatory sweating, and 
it has the advantages of being cheap and easy to take. 
Sedative drugs are a treatment method that works by sup-
pressing the mechanism by which symptoms appear when 
the patient is psychologically anxious, but these drugs can 
cause  the  side  effects  of  drowsiness  and  decrease  in 
motivation. Most primary hyperhidrosis patients are young 
and socially active, so this method of treatment cannot be 
used in many patients. Anticholinergic drugs act directly 
on the nerves in the sweat glands to show a perspiration 
suppression  effect  [14].  However,  anticholinergic  drugs 
suppress the sympathetic nervous system, so symptoms 
such as oral dryness, palpitations, constipation, dysuria, 
digestive problems, dizziness, and headaches can occur, 
and this method cannot be used in patients with underlying 
d i se a se s s u c h  a s  c a t a r a c t s o r  ur o l o gi c  d i se a se . D es p i t e 
t h e s e  d i s a d v a n t a g e s ,  a n t i c h o l i n e r g i c  d r u g s  a r e  s t i l l  t h e  
most  frequently  selected  oral  medication.  The  anticho-
linergic drug that is used the most often is glycopyrrolate. 
This drug has fewer central side effects, such as drowsi-
ness or headache, than other anticholinergic drugs, and it 
has a superior perspiration suppression effect, so it has 
been widely used overseas as the initial medication in hy-
perhidrosis treatment [3].
Glycopyrrolate is a drug originally developed for peptic 
ulcer disease, but it has a perspiration suppression effect, 
so it is now used frequently in hyperhidrosis treatment. 
Glycopyrrolate competes with acetylcholine at the muscar-
inic receptor to cause an anticholinergic effect. In addition, 
it is a drug in the highly polar quaternary ammonium group 
and cannot pass through lipid membranes, so it cannot 
penetrate the brain-nerve barrier and has little effect on 
the central nervous system. In contrast, atropine sulfate 
and scopolamine hydrobromide are highly non-polar ter-
tiary amines which can easily pass through lipid mem-
branes [9].
Our study analyzed the effect of orally administered 
gly copyrrolate in 36 primary hyperhidrosis patients. The 
study is meaningful in that it analyzed changes in everyday 
life, psychological state, quality of life, and the autonomic 
nervous system, in addition to actual decrease of perspi-
ration. Actual decrease of perspiration appeared in 75% of 32 Korean J Pain Vol. 25, No. 1, 2012
Fig. 3. Comparison of the total short form (SF) 36 score
of Pre- and post-glycopyrrolate medication groups. 
the patients who used the medication, and decreased level 
of discomfort in everyday life was also observed. Although 
changes in depression (BDI) and ANS scores could not be 
observed, symptoms of hyperhidrosis was suppressed and 
SF-36 score increased with the BAI score reduced, in-
dicating that the treatment could improve the actual social 
life of patients (Fig. 1-3).
Of course there are limitations to this study. First, it 
was difficult to compare the treatment with other medi-
cations. This was because of the limited number of pa-
tients and the difficulty in gathering a comparison group 
administered a different drug, due to ethical reasons. In 
addition,  the  study  was  mainly  based  on  questionnaire 
analysis, so confirmation of objective results was difficult.
When selecting a treatment method for hyperhidrosis, 
the current state of the patient and preference of the pa-
tient’s doctor can be influential. For a permanent effect, 
an  invasive  treatment  method  must  be  selected,  but  in 
genera l, f or saf e and r e v ersible initia l tr eatmen t, medi-
cation can be the solution. Therefore, the authors suggest 
glycopyrrolate as an effective drug that can reduce the de-
gree of hyperhidrosis and is safe and convenient for clinical 
use. 
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